Miklos Egyed (Egyed Miklos, Miklós Egyed)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 9

Top Topics

Sickle Cell Disease

Oral Anticoagulants

Chronic Lymphocytic Leukemia

Top Venues

European journal of haematology

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Miklos Egyed, Tóth Peter Oliver, Kellner Adam, Karadi Eva, Kollar Balazs, Kovacs Eszter, Pavlovics Anett, Gyori-Korom Viktoria, Herczeg Jozsef, Rajnics Peter
Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients. European journal of haematology (2024)
Stephen T Oh, Srdan Verstovsek, Vikas K Gupta, Uwe Platzbecker, Timothy Devos, Jean-Jacques Kiladjian, Donal P McLornan, Andrew Charles Perkins, Maria Laura Fox, Mary Frances McMullin, Adam J Mead, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Mei Huang, Bryan Strouse, Ruben Mesa
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis. EJHaem 5 (1) (2024)
Miklos Egyed, Tóth Peter Oliver, Kellner Adam, Karadi Eva, Kollar Balazs, Kovacs Eszter, Pavlovics Anett, Gyori-Korom Viktoria, Herczeg Jozsef, Rajnics Peter
Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients. European journal of haematology 113 (2) (2024)
Stephen T Oh, Srdan Verstovsek, Vikas K Gupta, Uwe Platzbecker, Timothy Devos, Jean-Jacques Kiladjian, Donal P McLornan, Andrew Charles Perkins, Maria Laura Fox, Mary Frances McMullin, Adam J Mead, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Mei Huang, Bryan Strouse, Ruben Mesa
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis. EJHaem 5 (1) (2024)
Stephen T Oh, Srdan Verstovsek, Vikas K Gupta, Uwe Platzbecker, Timothy Devos, Jean-Jacques Kiladjian, Donal P McLornan, Andrew Charles Perkins, Maria Laura Fox, Mary Frances McMullin, Adam J Mead, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Mei Huang, Bryan Strouse, Ruben Mesa
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis. EJHaem 5 (1) (2024)
Eva Karadi, Peter Dombi, Viktoria Gyorine Korom, Eszter Kovacs, Jozsef Herczeg, Hajnalka Andrikovics, Árpád Illés, Judit Demeter, Lajos Homor, Miklós Udvardy, Miklos Egyed
A potentially new thromboembolic event scoring system in polycythaemia vera patients: An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia register. European journal of haematology (2023)
Alexandre Theocharides, Heinz Gisslinger, Valerio De Stefano, Vincenzo Accurso, Alessandra Iurlo, Timothy Devos, Miklos Egyed, Eric Lippert, Regina Garcia Delgado, Nathan Cantoni, Anders E A Dahm, Damianos Sotiropoulos, Erik Houtsma, Aoife Smyth, Amir Iqbal, Paola Di Matteo, Mike Zuurman, Peter A W Te Boekhorst
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study. European journal of haematology (2023)
Miklos Egyed, Sandor Lueff, Judit Borbely, Arpad Illes
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. Future oncology (London, England) 18 (7) (2022)
Adam Kellner, Peter Dombi, Arpad Illes, Judit Demeter, Lajos Homor, Ibolya Ercsei, Zsofia Simon, Eva Karadi, Jozsef Herczeg, Viktoria Gy Korom, Zoltan Gasztonyi, Laszlo Szerafin, Miklos Udvardy, Miklos Egyed
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin. European journal of haematology 105 (4) (2020)